Innovation Debiopharm Academia Leman

Partnering with lemanic institutions to accelerate the translation of scientific innovation into new anti-cancer and anti-infective treatments

Debiopharm-Inartis

The Lemanic region has a rich ecosystem of scientific, academic and pharmaceutical organizations that focus on new breakthrough therapies for cancer patients. Through IDEAL, Debiopharm is aiming to accelerate the translation of scientific discoveries of the Lemanic region into therapeutic innovation with global reach. The initiative will allow Debiopharm to establish pre-agreed collaborations with academic and medical institutions to enable researchers to mature and tailor early-stage innovations in the field of oncology and antibiotics, with the financial support of Debiopharm, up to a stage where promising programs could be in-licensed for further development

How does IDEAL work?

You can help us to bring the next breakthrough treatment to patients

At Debiopharm, our development of innovative therapies targeting unmet medical needs in oncology starts by evaluating external innovation from multiple institutions worldwide. Our desire is to better leverage the potential in our local environment, the Lemanic region of Switzerland, to provide more therapeutic innovation by building a solid life science ecosystem that connects public institutions and private companies. We believe that working hand-in-hand with institutions in the region will lead to tomorrow’s solutions for patients worldwide.

If you have a promising early-stage oncology or anti-infective compound, you can send us your project proposal for review by our Steering Committee. If your project is selected for IDEAL funding, a research and development plan will be defined, allowing you access Debiopharm’s resources and expertise.

At the end of your project, a final report of your research and results will be sent to the Steering Committee for evaluation. The Steering Committee might ask for additional information or might request a to have further discussion:

  • For programs that could advance to become a Debiopharm development program, Debiopharm will communicate within 4 weeks its interest in continuing the project and will enter into negotiation for a partnership through license or research collaboration.
  • If the Steering Committee decides on the basis of the results that there will be no future development by Debiopharm (Debiopharm International SA and/or Debiopharm Research & Manufacturing), the Steering Committee will issue a negative decision, which releases the institute and the researcher from their obligations.

Our current partners

  • Université de Genève - Involved in most cutting-edge sectors and active in interdisciplinary research

  • IDEAL & ISPSO

    Institut des Sciences pharmaceutiques de Suisse occidentale - Conducts research to discover new therapeutic agents and develop novel formulation and delivery strategies

Frédéric Lévy Executive Director, Head of Search & Evaluation and Scientific Innovation, Debiopharm International S.A.

You would like to join the IDEAL program? We are always looking for new collaborations!

Contact us

Proposal Form

Download

Submit your project

If your scientifc project involves the early-stage development of new anti-cancer drugs and antibiotics, we invite you to submit your project for review. Please fill out the contact form below: